# KLOW MD — Frequently asked questions on the four-peptide blend

> Answers to the most common questions about the KLOW peptide blend: composition, mechanism, FDA and WADA status, the GLOW comparison, and the combination evidence gap.

Direct answers to the questions readers most often bring to the KLOW research. Each answer cites the underlying paper or regulatory record.

## What is in the KLOW peptide blend?

KLOW is a community designation for a four-peptide research co-formulation. The most-cited research-vial composition is 80 mg total per vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg. A 5 mg: 5 mg: 5 mg: 10 mg balanced variant is also marketed by some vendors. The four peptides are co-dissolved at fixed mass ratios in a single research vial; they do not form a single chemical complex. The K-L-O-W letters are a marketing mnemonic and do not correspond to any chemical naming convention.

## What is the difference between KLOW and GLOW peptide stacks?

GLOW refers to a three-peptide research co-formulation of GHK-Cu, BPC-157, and TB-500. KLOW is explicitly the GLOW blend extended with KPV, the anti-inflammatory C-terminal tripeptide of alpha-MSH. In mechanistic terms the addition supplies an NF-κB-inhibition arm to the otherwise regenerative-focused three-peptide stack [1][2][3]. No controlled head-to-head study of GLOW versus KLOW has been published, so the practical impact of adding KPV to the three-peptide combination has not been measured in any animal or human model.

## Has any controlled study tested the four-peptide KLOW blend itself?

No. No controlled in-vivo study has tested the four-peptide KLOW blend against monotherapy of any single component, against any pairwise or three-peptide subset, or against placebo. The full body of evidence consists of single-agent studies on KPV [1][2][3][4][5][6], GHK-Cu [7][8][9][10][11][22], BPC-157 [12][13][14][20][21], and TB-500 or native Tβ4 [15][16][17][18][19]. Synergy claims for the blend are mechanistic extrapolations from this single-agent literature, not experimental findings.

## Is the KLOW blend FDA-approved?

No. Neither the KLOW blend as a whole nor any of its four individual components is approved by the U.S. Food and Drug Administration for any human indication.

In September 2023, the FDA placed BPC-157 and TB-500 on its Category 2 list of bulk drug substances of safety concern, effectively prohibiting 503A and 503B compounding pharmacies from producing them. In April 2026, FDA removed both from Category 2 following nomination withdrawal, but neither was moved to Category 1 (permitted-for-compounding), leaving them in a regulatory gray zone. BPC-157, TB-500, and KPV-related bulk drug substances are scheduled for FDA Pharmacy Compounding Advisory Committee evaluation on July 23, 2026.

GHK-Cu is widely used in topical cosmetic products under cosmetic-ingredient rules but has no FDA approval as a systemic or injectable drug. KPV has not received FDA approval for any indication.

## Is the KLOW blend banned by WADA?

Two of the four components are on the World Anti-Doping Agency prohibited list. TB-500 is explicitly prohibited at all times under category S2 (growth factors and growth-factor modulators). BPC-157 is listed under category S0 (non-approved substances), effective 2022. GHK-Cu and KPV are not specifically named on the WADA prohibited list as of 2026.

Because the KLOW blend contains BPC-157 and TB-500, athletes subject to WADA testing should treat the entire blend as prohibited.

## What does the research say about KPV?

KPV is the C-terminal tripeptide of alpha-MSH (residues 11-13). The strongest preclinical signal is in inflammatory bowel disease models — Dalmasso showed 10 nM KPV inhibits NF-κB and MAPK signaling in human intestinal epithelial cells and that oral KPV in drinking water reduces DSS- and TNBS-colitis severity in mice, with PepT1 identified as the cellular entry transporter [1]. Kannengiesser confirmed activity in DSS and CD45RBhi transfer colitis, and importantly showed full rescue from DSS mortality in MC1R-deficient mice, indicating melanocortin-receptor-independent action [2]. Mechanism work by Land established that KPV blocks p65-importin-α3 binding to prevent NF-κB nuclear translocation [3]. Recent work extends the signal to traumatic brain injury [4], PM10-induced keratinocyte pyroptosis [6], and PepT1-targeted nanoparticle delivery for colitis [5].

## What does the research say about GHK-Cu?

GHK-Cu is an endogenous copper-binding tripeptide isolated from human plasma in 1973, whose circulating concentration declines with age. Pickart and Margolina's 2018 review reported that at 1-10 nM in cultured fibroblasts GHK-Cu altered expression of about 4,192 human genes (31.2 percent of the protein-coding genome), with strongest signals on extracellular-matrix remodeling, antioxidant defense, anti-inflammatory pathways, and DNA repair [7]. Campbell showed 10 nM GHK reversed an emphysematous-destruction gene signature in COPD lung fibroblasts [8]. Mao demonstrated that 20 mg/kg oral GHK-Cu × 14 days reduced TNF-α, IL-6, and IL-1β in DSS colitis with SIRT1 upregulation and Th17 suppression [9]. Topical wound-healing data is substantial [10][22] and includes a 67-women cosmetic trial outperforming vitamin C and retinoic acid on collagen deposition [11].

## What does the research say about BPC-157?

BPC-157 is a 15-amino-acid synthetic peptide derived from a fragment in human gastric juice. The reproducible preclinical signal is in connective-tissue and gastrointestinal repair — Krivic showed tendon-to-bone healing in rats at 10 μg/kg IP [12], Cerovecki demonstrated MCL healing across IP, topical, and oral routes [13], and Novinscak showed muscle-crush recovery [14]. Vasireddi's 2025 systematic review of 36 studies confirmed robust preclinical effects on growth-hormone-receptor expression, angiogenesis, and inflammatory cytokine reduction but identified only three human pilot studies and explicitly cautioned against off-label clinical use outpacing the human evidence [20]. A 2025 narrative review framed the risk-benefit tradeoff around chronic angiogenic exposure and a sub-30-minute plasma half-life [21]. Most BPC-157 work originates from the Sikiric / Seiwerth group in Zagreb; independent replication outside that lab is comparatively sparse.

## What does the research say about TB-500?

TB-500 is a synthetic seven-amino-acid acetylated fragment of native thymosin beta-4 (Ac-LKKTETQ-OH), containing the LKKTET actin-binding motif. The most important caveat for any reader is that nearly all published preclinical data attributed to 'thymosin beta-4' uses the full 43-amino-acid Tβ4 protein, not the seven-amino-acid TB-500 fragment. The underlying Tβ4 literature includes G-actin sequestration biochemistry [15], 42-61 percent acceleration of rat dermal punch wound re-epithelialization [16], corneal healing after alkali burn in mice [17], PINCH-Tβ4-ILK Akt activation with improved cardiac function after MI [18], and adult epicardial progenitor mobilization [19]. Fragment-level activity has been demonstrated in some dermal wound paradigms but not in most of the cardiac, ocular, and progenitor-mobilization studies. Marketing language across the research-peptide industry routinely conflates the fragment and the full-length protein.

## Why does the KLOW blend contain mostly GHK-Cu by mass?

The canonical 80 mg vial allocates 50 mg to GHK-Cu and 10 mg each to BPC-157, TB-500, and KPV — making GHK-Cu 62.5 percent of vial mass. Three factors plausibly explain the asymmetry. First, GHK-Cu is the smallest molecule of the four by molecular weight after KPV (340 Da versus 1,419 Da for BPC-157), so equal molar amounts would still tilt mass toward the tripeptides. Second, GHK-Cu's most-studied effective concentrations are in the nanomolar range in vitro [7][8] but its in-vivo work has used much higher absolute amounts (20 mg/kg oral gavage in murine colitis [9]). Third, the regenerative-rationale framing centers GHK-Cu as the broad gene-expression modulator and treats the other three as targeted accessories. There is no controlled study establishing that the 50:10:10:10 mg ratio is the right one — it is a vendor convention.

## What is the most-cited KLOW blend research-vial composition?

The most-cited research-vial composition across multiple compounders (Loti Labs, Peptide Sciences, BioLongevity, Simple Peptide, Eternal Peptides, Penguin Peptides, Profound Aminos, Peptides Biotech, Alpha Biomed, Luminous Peptides) is a single 80 mg vial containing GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg. A balanced 5 mg : 5 mg : 5 mg : 10 mg variant is also marketed. Component ratios vary by vendor; mass-spectrometric verification of composition is rarely supplied with vendor certificates of analysis.

## What is the regulatory status of the KLOW components in 2026?

BPC-157 and TB-500 were placed on FDA Category 2 (bulk drug substances of safety concern) in September 2023, effectively prohibiting 503A and 503B compounding. In April 2026, both were removed from Category 2 following nomination withdrawal, but neither was moved to Category 1 (permitted-for-compounding). BPC-157, TB-500, and KPV-related bulk drug substances are scheduled for FDA Pharmacy Compounding Advisory Committee evaluation on July 23, 2026.

GHK-Cu has decades of human topical cosmetic data and is widely used in cosmetic products under cosmetic-ingredient rules; it has no FDA approval as a systemic or injectable drug. KPV has not received FDA approval for any indication. WADA-wise, TB-500 is banned at all times (S2) and BPC-157 is listed under S0; GHK-Cu and KPV are not specifically named on the WADA prohibited list as of 2026.

## What is KLOW MD — is this a clinic?

No. KLOW MD is an independent editorial project that publishes summaries of the peer-reviewed research literature on the KLOW research-peptide blend and its four components. We are not a clinic. We do not employ clinicians. We do not provide medical advice. We do not manufacture, sell, or distribute any product. The 'MD' in the domain refers to monograph and desk-reference editorial framing — the way a physician's-desk-reference entry treats a substance — not a representation that the publisher is a licensed physician or operates a medical practice.

## Where can I read the underlying studies?

Every claim on this site cites a specific paper with DOI and PubMed or PMC link. The full reference list is on the /references page, where citations can be sorted by year, journal, or component peptide. Outbound links go to PubMed, PubMed Central, ClinicalTrials.gov, and the peer-reviewed journal of publication — never to a vendor or commercial source.

---

An independent editorial monograph on the four-peptide KLOW research blend — not a clinic, not a pharmacy, not a vendor.